PharmiWeb.com - Global Pharma News & Resources
18-Oct-2022

STRATEC REPORTS PRELIMINARY FIGURES FOR FIRST NINE MONTHS OF 2022 AND ADJUSTS SALES GUIDANCE

STRATEC SE / Key word(s): Preliminary Results/Change in Forecast
STRATEC REPORTS PRELIMINARY FIGURES FOR FIRST NINE MONTHS OF 2022 AND ADJUSTS SALES GUIDANCE

18-Oct-2022 / 20:24 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


STRATEC REPORTS PRELIMINARY FIGURES FOR FIRST NINE MONTHS OF 2022 AND ADJUSTS SALES GUIDANCE

Birkenfeld, October 18, 2022

Based on preliminary figures, STRATEC expects to report consolidated sales of € 207.7 million for the first nine months of 2022 (9M/2021: € 225.4 million). This corresponds to a year-on-year reduction in sales by 7.9% (constant currency: -11.7%). This reduction was chiefly due to the previous year’s high pandemic-related basis of comparison, as well to the ongoing highly tense situation in supply chains. Contrary to original expectations, delivery backlogs rose further throughout the third quarter of 2022 given the continuing difficulties in procuring upstream products (particularly semiconductor chips).

Preliminary calculations indicate an adjusted EBIT margin of 18.3% for the first nine months of 2022 (9M/2021: 21.6%). The margin is thus within the target corridor communicated for the full financial year (16.5% to 18.5%). Alongside negative economies of scale relating to lower sales volumes, the margin was as expected also negatively influenced by a weaker product mix within the Systems business. The third quarter of 2022 nevertheless brought a clear increase in profitability compared with the first half of 2022. This was driven in particular by high earnings contributions from development services, some of which had been budgeted for recognition in the second quarter of 2022 already.

Given the ongoing highly tense supply chain situation, STRATEC no longer expects to make up for existing delivery backlogs by the end of the year to the extent originally planned. The Board of Management of STRATEC has therefore decided to adjust its guidance for the sales performance. On a constant-currency basis, sales in the 2022 financial year are now expected to decrease by around 5.0% to 8.0% (nominal sales reduction of around 1.0% to 4.0%). Previously, the company had forecast constant-currency sales at the previous year’s level. The guidance for the adjusted EBIT margin, which is forecast at around 16.5% to 18.5% in the 2022 financial year (2021: 18.9%), has been confirmed.

STRATEC will publish its Quarterly Statement with the complete figures for the first nine months of 2022 on November 3, 2022. Moreover, a conference call/audio webcast will be held in English on November 3, 2022.

FURTHER INFORMATION IS AVAILABLE FROM:
STRATEC SE
Jan Keppeler | Investor Relations, Sustainability & Corporate Communications
Tel: +49 7082 7916-6515
ir@stratec.com
www.stratec.com


18-Oct-2022 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: STRATEC SE
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec.com
Internet: www.stratec.com
ISIN: DE000STRA555
WKN: STRA55
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1466399

 
End of Announcement EQS News Service

Editor Details

Last Updated: 18-Oct-2022